Gatifloxacin hydrochloride 加替沙星盐酸盐; AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride|cas:121577-32-0|西域试剂

Gatifloxacin hydrochloride 加替沙星盐酸盐; AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride,99.94%

产品编号：Bellancom-10581A| CAS NO：121577-32-0| 分子式：C₁₉H₂₃ClFN₃O₄| 分子量：411.86

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-10581A	￥400.00	杭州北京（现货）
Bellancom-10581A	￥500.00	杭州北京（现货）
Bellancom-10581A	￥1934.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Gatifloxacin hydrochloride 加替沙星盐酸盐; AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

产品介绍

Gatifloxacin hydrochloride (AM-1155 hydrochloride) 是一种有效的氟喹诺酮类抗生素 (antibiotic)，具有广谱抗菌活性。Gatifloxacin hydrochloride (AM-1155 hydrochloride) 可抑制细菌 II 型拓扑异构酶 (type II topoisomerases) (IC₅₀=13.8 μg/ml; 金黄色葡萄球菌拓扑异构酶 IV) 和大肠杆菌 DNA 解旋酶 (IC₅₀=0.109 μg/ml)。Gatifloxacin hydrochloride (AM-1155 hydrochloride) 在动物模型中，可用于细菌性结膜炎的研究。

生物活性

Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

体外研究

Gatifloxacin hydrochloride is against S. aureus MS5935 topoisomerase IV, E. coli NIHJ JC-2 DNA gyrase and HeLa cell topoisomerase II with IC₅₀ values of 13.8 μg/ml, 0.109 μg/ml, and 265 μg/ml, respectively.
Gatifloxacin hydrochloride is against S. aureus MS5935 topoisomerase IV, E. coli NIHJ JC-2 DNA gyrase and HeLa cell topoisomerase II with MIC values of 0.05 μg/ml, 0.0063 μg/ml, and 122 μg/ml, respectively.
Gatifloxacin hydrochloride exhibits antibacterial activities for wild-type strains (MS5935, MS5952, MR5867 and MR6009) the first-, second-, third-, and fourth-step mutants with MIC values of 0.05 to 0.10 μg/ml, 0.20 μg/ml, 1.56 to 3.13 μg/ml, 1.56 to 6.25 μg/ml, and 50 to 200 μg/ml, respectively. Gatifloxacin hydrochloride displays the most potent activity against the second- and third-step mutants (MS5952, MR5867 and MR6009) except for the second-step mutant of strain MS5935.
Gatifloxacin hydrochloride has potent activity against norA transformant NY12 (MIC, 0.39 μg/ml).
Gatifloxacin hydrochloride (20-100 μM; 72 hours) significantly decreases insulin content to 60% at Day 1, and continues to be reduced to 50.1% and 44.7% at Day 3 by 20 μM and 100 μM Gatifloxacin hydrochloride, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Gatifloxacin hydrochloride (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice with Nocardia brasiliensis in the right hind footpad
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3 times a day; 30 days
Result:	Reduced the production of lesions in mice.

体内研究

Gatifloxacin hydrochloride (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice with Nocardia brasiliensis in the right hind footpad
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3 times a day; 30 days
Result:	Reduced the production of lesions in mice.

性状

Solid

溶解性数据

In Vitro:

H₂O : 10 mg/mL (24.28 mM; Need ultrasonic)

DMSO : 4 mg/mL (9.71 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4280 mL	12.1400 mL	24.2801 mL
5 mM	0.4856 mL	2.4280 mL	4.8560 mL
10 mM	0.2428 mL	1.2140 mL	2.4280 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶